2. Search Result
Search Result
Results for "

inward

" in MedChemExpress (MCE) Product Catalog:

94

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dyes

1

Biochemical Assay Reagents

9

Peptides

6

Natural
Products

7

Isotope-Labeled Compounds

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-19545A
    SCH-23390 hydrochloride
    Maximum Cited Publications
    31 Publications Verification

    R-(+)-SCH-23390 hydrochloride

    		 Dopamine Receptor 5-HT Receptor Potassium Channel Neurological Disease
    SCH-23390 hydrochloride (R-(+)-SCH-23390 hydrochloride) is a potent and selective dopamine D1-like receptor antagonist with Kis of 0.2 nM and 0.3 nM for the D1 and D5 receptor, respectively. SCH-23390 hydrochloride is a potent and high efficacy human 5-HT2C receptor agonist with a Ki of 9.3 nM. SCH-23390 hydrochloride also binds with high affinity to the 5-HT2 and 5-HT1C receptors. SCH-23390 hydrochloride inhibits G protein-coupled inwardly rectifying potassium (GIRK) channels with an IC50 of 268 nM .
    SCH-23390 hydrochloride
  • HY-B0280
    Ranolazine
    4 Publications Verification

    CVT 303; RS 43285-003

    		 Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine
  • HY-17001A
    Flupirtine
    1 Publications Verification

    D 9998

    		 Potassium Channel iGluR GABA Receptor Neurological Disease Inflammation/Immunology
    Flupirtine (D 9998) is an orally active, blood-brain barrier-crossing non-opioid analgesic and neuroprotective agent. Flupirtine is a neuronal potassium channel opener (Kv7 activator), a NMDA receptor antagonist and a GABA receptor activator. Flupirtine stabilizes blood-brain-barrier integrity, reduces oxidative stress and brain leukocyte infiltration, enhances angioneurogenesis, suppresses calcium influx, stabilizes neuronal resting membrane potential, and counteracts focal cerebral ischemia. Flupirtine exhibits analgesic, muscle relaxant properties, protects neurons from excitotoxic, ischemic, or cytokine-mediated death. Flupirtine functions as a non-opioid analgesic without antipyretic or antiphlogistic properties, shows no relevant affinity to opiate receptor. Flupirtine can be used for the research of focal cerebral ischemia, pain, Alzheimer’s disease, or multiple sclerosis .
    Flupirtine
  • HY-A0170
    Trovafloxacin
    5+ Cited Publications

    		 Bacterial Topoisomerase Antibiotic Infection
    Trovafloxacin is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .
    Trovafloxacin
  • HY-103399
    Trovafloxacin mesylate
    5+ Cited Publications

    		 Bacterial Topoisomerase Antibiotic Infection
    Trovafloxacin mesylate is a broad-spectrum quinolone antibiotic with potent activity against Gram-positive, Gram-negative and anaerobic organisms. Trovafloxacin mesylate blocks the DNA gyrase and topoisomerase IV activity. Trovafloxacin mesylate is also a potent, selective and orally active pannexin 1 channel (PANX1) inhibitor with an IC50 of 4 μM for PANX1 inward current. Trovafloxacin mesylate does not inhibit connexin 43 gap junction or PANX2. Trovafloxacin mesylate leads to dysregulated fragmentation of apoptotic cells by inhibiting PANX1 .
    Trovafloxacin mesylate
  • HY-B0920
    Tolazamide
    2 Publications Verification

    U-17835

    		 Potassium Channel Metabolic Disease Endocrinology
    Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA .
    Tolazamide
  • HY-12882A
    Ifenprodil tartrate
    5+ Cited Publications

    NP-120 tartrate; RC-61-91 tartrate

    		 iGluR Adrenergic Receptor Potassium Channel Calcium Channel Influenza Virus Infection Neurological Disease
    Ifenprodil (NP-120) tartrate, a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil tartrate exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil tartrate is an α1 adrenergic receptor antagonist. Ifenprodil tartrate inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil tartrate has reliable inhibitory effects against A/H1N1 strains (EC50 of 6.6 µM). Ifenprodil tartrate has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil tartrate can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease .
    Ifenprodil tartrate
  • HY-17401
    Ranolazine dihydrochloride
    4 Publications Verification

    CVT 303 dihydrochloride; RS 43285

    		 Calcium Channel Sodium Channel Autophagy Cardiovascular Disease Cancer
    Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .
    Ranolazine dihydrochloride
  • HY-12533
    Disopyramide
    2 Publications Verification

    Dicorantil; SC-7031

    		 Sodium Channel Potassium Channel Cardiovascular Disease
    Disopyramide (Dicorantil) is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide inhibits HERG encoded potassium channels. Disopyramide also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide
  • HY-B0549A
    Flavoxate hydrochloride

    Rec-7-0040; DW61

    		 Calcium Channel Adenosine Receptor mAChR Dopamine Receptor Adrenergic Receptor Cardiovascular Disease Infection Neurological Disease Cancer
    Flavoxate hydrochloride (Rec-7-0040; DW61) is an orally active L-type Ca 2+ channel inhibitor and antispasmodic. Flavoxate hydrochloride inhibits cyclic adenosine monophosphate production by blocking voltage-dependent inward Ba 2+ currents, regulating the brainstem micturition center, and stimulating G protein-coupled receptors. Consequently, Flavoxate hydrochloride induces relaxation of bladder smooth muscle and inhibits isovolumetric rhythmic contractions. Flavoxate hydrochloride effectively increases bladder capacity and alleviates symptoms of urgent urination frequency and pollakiuria caused by overactive bladder. Flavoxate hydrochloride can be used in research on overactive bladder and related voiding dysfunctions .
    Flavoxate hydrochloride
  • HY-125176
    G907
    1 Publications Verification

    		 Bacterial Infection
    G907 is a selective antagonist of ATP-binding cassette (ABC) transporter MsbA with anti-microbial activity. G907 inhibits E. coli MsbA with an IC50 value of 18 nM. G907 traps MsbA in an inward-facing, lipopolysaccharide-bound conformation by wedging into an architecturally conserved transmembrane pocket .
    G907
  • HY-118504
    Sulfoxaflor
    1 Publications Verification

    		 Environmental Pollutants nAChR Neurological Disease
    Sulfoxaflor is an orally active full agonist of insect nicotinic acetylcholine receptors (nAChRs), targeting the α-bungarotoxin-insensitive nAChR1 and nAChR2 subtypes. Sulfoxaflor binding to nACh is not inhibited by d-Tubocurarine (HY-125901), but is partially inhibited by Mecamylamine (HY-B1395A). Sulfoxaflor induces inward currents by activating nAChRs, leading to insect neurotoxicity. Sulfoxaflor can be used in the research of agricultural pest control, pesticide toxicology, insect neural receptor pharmacology, etc .
    Sulfoxaflor
  • HY-B1194
    Tetramisole hydrochloride

    (±)-Tetramisole hydrochloride; DL-Tetramisole hydrochloride; R-829

    		 Potassium Channel Parasite PKA Infection Cardiovascular Disease
    Tetramisole hydrochloride is an orally active, selective inward rectifier potassium channel agonist with an EC50 of approximately 30 μM for the Kir2.1 subunit. Tetramisole hydrochloride is also an anti-nematode agent that blocks neuromuscular transmission by non-competitive depolarization. Tetramisole hydrochloride promotes the forward transport of Kir2.1 channels, hyperpolarizes the resting potential (RP), shortens the action potential duration (APD), inhibits intracellular calcium overload and the PKA signaling pathway, and exerts anti-arrhythmic and anti-myocardial remodeling activities. Tetramisole hydrochloride can be used in cardiac electrophysiology research and research related to myocardial ischemia and heart failure .
    Tetramisole hydrochloride
  • HY-N2338
    Cholesterol myristate

    Cholesteryl myristate; Cholesteryl tetradecanoate

    		 nAChR GABA Receptor Potassium Channel Endogenous Metabolite Cancer
    Cholesterol myristate is a natural steroid present in traditional Chinese medicine. Cholesterol myristate binds to several ion channels such as the nicotinic acetylcholine receptor, GABAA receptor, and the inward-rectifier potassium ion channel.
    Cholesterol myristate
  • HY-107757
    GMQ hydrochloride

    2-Guanidine-4-methylquinazoline hydrochloride

    		 Sodium Channel Neurological Disease
    GMQ (hydrochloride) is a ASIC (acid-sensing ion) channel activator with an EC50 value of 1.83 mM for ASIC3 at pH 7.4. GMQ (hydrochloride) opens only ASIC3 but no other ASICs at pH 7.4. GMQ (hydrochloride) can be used for neurological disease research .
    GMQ hydrochloride
  • HY-127106
    VU0810464
    1 Publications Verification

    		 Potassium Channel Neurological Disease
    VU0810464 is a potent and selective non-ureaG protein-gated inwardly-rectifying potassium channels (GIRK, Kir3) activator. VU0810464 displays nanomolar potency for neuronal (EC50=165 nM) and GIRK1/4 (EC50=720 nM) channels with improved brain penetration .
    VU0810464
  • HY-B0883
    3,6-Diaminoacridine hemisulfate
    3 Publications Verification

    		 Bacterial Fluorescent Dye Potassium Channel DNA/RNA Synthesis Infection Neurological Disease Cancer
    3,6-Diaminoacridine hemisulfate is a multifunctional acridine compound. 3,6-Diaminoacridine hemisulfate is an acridine dye and also a DNA inserter. 3,6-Diaminoacridine hemisulfate is a potent broad-spectrum antibacterial agent. Its mechanism is to insert into bacterial DNA, interfering with replication and transcription, leading to bacterial lysis. 3,6-Diaminoacridine hemisulfate is a Kir3.2 potassium channel blocker and can be used to study the neurological phenotype of Down syndrome. 3,6-Diaminoacridine hemisulfate can penetrate the stratum corneum of the skin and accumulate in the cell nucleus. Long-term exposure may induce skin cancer or other malignant tumors .
    3,6-Diaminoacridine hemisulfate
  • HY-12533A
    Disopyramide phosphate
    2 Publications Verification

    Dicorantil phosphate; SC-7031 phosphate

    		 Potassium Channel Sodium Channel Cardiovascular Disease
    Disopyramide phosphate is a class IA antiarrhythmic agent with efficacy in ventricular and atrial arrhythmias. Disopyramide phosphate blocks the fast inward sodium current of cardiac muscle and prolongs the duration of cardiac action potentials. Disopyramide phosphate inhibits HERG encoded potassium channels. Disopyramide phosphate also exhibits complex protein binding, and has a potent negative inotropic action .
    Disopyramide phosphate
  • HY-13422
    Zatebradine hydrochloride
    2 Publications Verification

    UL-FS-49; UL-FS-49CL

    		 HCN Channel Cardiovascular Disease
    Zatebradine (UL-FS-49 (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC50 values 1.96 µM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC50 values of 1.83 µM, 2.21 µM, 1.90 µM and 1.88 µM, respectively .
    Zatebradine hydrochloride
  • HY-P10856
    CPI1

    		P-glycoprotein Cancer
    CPI1 is a multidrug resistance protein 1 (MRP1) inhibitor with a Ki value of 100 nM. CPI1 binds to the same substrate-binding site as leukotriene C4, stabilizes MRP1 in an apo-like inward-facing conformation, blocks the conformational changes required for ATP hydrolysis and substrate transport, and inhibits the ATPase activity of human and bovine MRP1. CPI1 serves as a tool for investigating the substrate transport mechanism of MRP1. CPI1 is applicable to research related to cancer multidrug resistance .
    CPI1
  • HY-100607A
    Landiolol hydrochloride

    ONO1101 hydrochloride

    		 Adrenergic Receptor Calcium Channel Potassium Channel Reactive Oxygen Species (ROS) Cardiovascular Disease Inflammation/Immunology Endocrinology
    Landiolol (ONO1101) hydrochloride is a highly selective, ultra-short-acting competitive inhibitor of β1 adrenergic receptors. Landiolol hydrochloride specifically blocks cardiac β1 receptors, reducing heart rate and myocardial oxygen consumption. Landiolol hydrochloride inhibits TNF-α-induced excessive mitochondrial oxygen consumption and reactive oxygen species production in a sepsis model, alleviating renal injury. Landiolol hydrochloride has little effect on cardiac ion channels (such as L-type calcium current and inward rectifier potassium current) and has a weak negative inotropic effect. Landiolol hydrochloride can be used for perioperative tachycardia control and protection studies of sepsis-related acute kidney injury .
    Landiolol hydrochloride
  • HY-12882
    Ifenprodil
    5+ Cited Publications

    NP-120; RC-61-91

    		 iGluR Adrenergic Receptor Potassium Channel Calcium Channel Influenza Virus Infection Neurological Disease
    Ifenprodil (NP-120), a cerebral vasodilator, is a noncompetitive NMDA receptor antagonist. Ifenprodil exerts high affinity at NR1A/NR2B receptors (IC50=0.34 μM) over 400-fold than at NR1A/NR2A receptors (IC50=146 μM) . Ifenprodil is an α1 adrenergic receptor antagonist. Ifenprodil inhibits GIRK (Kir3), reduces inward currents through the basal GIRK activity. Ifenprodil has reliable inhibitory effects against A/H1N1 strains (EC50 of 6.6 µM). Ifenprodil has neuroprotective, anticonvulsant and antinociceptive effects. Ifenprodil can be used for the study of cerebrovascular diseases and peripheral arterial obliterative disease .
    Ifenprodil
  • HY-108608
    o-3M3FBS

    		Calcium Channel Others
    o-3M3FBS is the negative control of m-3M3FBS. o-3M3FBS inhibits inward and outward currents via mechanisms independent of PLC acting in an antagonistic manner. In contrast, o-3M3FBS also causes an increase in [Ca 2+]i in an agonistic manner .
    o-3M3FBS
  • HY-118607
    VU041

    		Potassium Channel Parasite Infection
    VU041 is a first submicromolar-affinity inhibitor of Anopheles (An.) gambiae and Aedes (Ae.) aegypti inward rectifier potassium 1 (Kir1) channels with IC50 values of 2.5 μM and 1.7 μM, respectively. VU041 inhibits appreciably is mammalian Kir2.1 (IC50 of 12.7 μM), and has less inhibitory effect on mammalian Kir1.1, Kir4.1, Kir6.2/SUR1, and Kir7.1. VU041 also induces impaired Malpighian tubule function .
    VU041
  • HY-135783
    AT 1001
    1 Publications Verification

    		 nAChR Neurological Disease Metabolic Disease Inflammation/Immunology
    AT 1001 is an orally effective α3β4 nicotinic acetylcholine receptor (α3β4 nAChR) antagonist with a Ki value of 2.64 nM. AT 1001 reversibly blocks Epibatidine (HY-101078)-induced inward currents in HEK cells transfected with α3β4 nAChR. AT 1001 dose-dependently blocks nicotine self-administration behavior in rats, alleviates gluten-induced gastrointestinal symptoms, blocks tight junction toxin-induced immune responses, and reduces the incidence of type 1 diabetes in rats. AT 1001 can be used in the research of nicotine addiction and celiac disease .
    AT 1001
  • HY-N6868
    Dimethyl lithospermate B

    dmLSB

    		 Sodium Channel Cardiovascular Disease
    Dimethyl lithospermate B (dmLSB) is a selective Na + channel agonist. Dimethyl lithospermate B slows inactivation of sodium current (INa), leading to increased inward current during the early phases of the action potential (AP) .
    Dimethyl lithospermate B
  • HY-13422A
    Zatebradine
    2 Publications Verification

    UL-FS-49 free base; UL-FS-49CL free base

    		 HCN Channel Cardiovascular Disease
    Zatebradine (UL-FS-49 (free base); UL-FS-49CL (free base)) is a potent inhibitor of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels with an IC50 value of 1.96 µM. Zatebradine blocks the slow inward current through human HCN1, HCN2, HCN3 and HCN4 channels, with IC50 values of 1.83 µM, 2.21 µM, 1.90 µM and 1.88 µM, respectively .
    Zatebradine
  • HY-108595
    VU590
    2 Publications Verification

    		 Potassium Channel Others
    VU590 is a potent and moderately selective ROMK (Kir1.1) inhibitor, with an IC50 of 290 nM. VU590 also inhibits Kir7.1, with an IC50 of 8 μM. VU590 is not a good probe of ROMK function in the kidney .
    VU590
  • HY-112544
    IK1 inhibitor PA-6
    1 Publications Verification

    PA-6

    		 Potassium Channel Cardiovascular Disease
    IK1 inhibitor PA-6 (PA-6), a pentamidine analogue, is a selective and potent IK1 (KIR2.x ion-channel-carried inward rectifier current) inhibitor, with IC50 values of 12-15 nM for human and mouse KIR2.x currents. IK1 inhibitor PA-6 (PA-6) elevates KIR2.1 protein expression and induces intracellular KIR2.1 accumulation. IK1 inhibitor PA-6 (PA-6) has the potential to treat atrial fibrillation and arrhythmia .
    IK1 inhibitor PA-6
  • HY-19434
    trans-ACPD

    Trans-(±)-ACP

    		 mGluR Metabolic Disease
    trans-ACPD, a metabotropic receptor agonist, produces calcium mobilization and an inward current in cultured cerebellar Purkinje neurons.
    trans-ACPD
  • HY-114633
    VU625
    2 Publications Verification

    		 Potassium Channel Others
    VU625 is an inhibitor for potassium channel, that selectively inhibits mosquito Aedes aegypti inward rectifier potassium channel 1 (AeKir), with IC50 of 96.8 nM in HEK293 cell. VU625 can be used in development of insecticide .
    VU625
  • HY-139064
    NPBA

    		Potassium Channel Neurological Disease Inflammation/Immunology
    NPBA, a potassium K2P channel TASK-3 (KCNK9) agonist, is a tandem pore domain weak inward rectifying K + channel (TWIK2) channel blocker. NPBA suppresses NLRP3 inflammasome activation in macrophages .
    NPBA
  • HY-178058A
    VU6080824 hydrochloride

    		Potassium Channel Others
    VU6080824 (hydrochloride), a derivative of ML-133 (HY-100230), is an inward-rectifier potassium channel (Kir2.1) inhibitor with an IC50 of 0.35  μM. VU6080824 (hydrochloride) has superior thallium flux and manual patch clamp (MPC) functional potency .
    VU6080824 hydrochloride
  • HY-108960
    PPADS

    		P2X Receptor Interleukin Related Neurological Disease
    PPADS is a P2X receptor (P2X Receptor) antagonist and a reversible competitive antagonist of NAADP receptors, with IC50 values of 68 nM (P2X1) and 214 nM (P2X3), respectively. PPADS alleviates pain-related behaviors in the central and peripheral nervous systems of mice after peripheral neuropathy, inhibits the overproduction of IL-1β, IL-6, iNOS and nNOS, and suppresses the hydrolytic activity of extracellular ATPase. PPADS blocks ATP-mediated inward currents on recombinant rat P2X1 and P2X3 receptors, and inhibits purinergic nerve stimulation-induced contraction of rabbit bladder detrusor muscle. PPADS is applicable to research related to neuropathic pain .
    PPADS
  • HY-137325A
    2-Chloro-ATP sodium

    		Calcium Channel Metabolic Disease
    2-Chloro-ATP sodium (2-Chloro ATP) is an adenine nucleotide and an analog of ATP. It is an antagonist of the purinergic P2Y1 receptor and inhibits intracellular calcium mobilization induced by ADP (HY-W010918) in Jurkat cells expressing the human receptor (Ki=2.3 μM). 2-Chloro-ATP sodium is an agonist of the purinergic P2X receptor and induces inward currents in HEK293 cells expressing human bladder smooth muscle or rat PC12 forms of the receptor (EC50=0.5 and 2.5 μM). 2-Chloro-ATP sodium induces relaxation of precontracted guinea pig cecal strips in a concentration-dependent manner. 2-Chloro-ATP sodium has been used to study the substrate specificity of cyclic nucleotide-dependent protein kinases such as protein kinase A (PKA) and PKG.
    2-Chloro-ATP sodium
  • HY-P1218B
    Phrixotoxin 3-NH2 TFA

    		Sodium Channel Neurological Disease
    Phrixotoxin 3-NH2 TFA is a derivative of Phrixotoxin 3 TFA (HY-P1218A). Phrixotoxin 3 TFA is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 TFA modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .
    Phrixotoxin 3-NH2 TFA
  • HY-129496
    NP-313

    		Thrombin Cardiovascular Disease
    NP-313 is a potent antithrombotic agent that inhibits platelet aggregation and activation. NP-313 has dual inhibition of thromboxane A 2 synthesis and selective inhibition of SOCC-mediated Ca 2+ inward flow .
    NP-313
  • HY-P1218
    Phrixotoxin 3

    		Sodium Channel Neurological Disease
    Phrixotoxin 3 is a potent blocker of voltage-gated sodium channels, with IC50s of 0.6, 42, 72, 288, 610 nM for NaV1.2, NaV1.3, NaV1.4, NaV1.1 and NaV1.5, respectively. Phrixotoxin 3 modulates voltage-gated sodium channels with properties similar to those of typical gating-modifier toxins, both by causing a depolarizing shift in gating kinetics and by blocking the inward component of the sodium current .
    Phrixotoxin 3
  • HY-B0549
    Flavoxate

    Rec-7-0040 free base; DW61 free base

    		 mAChR Calcium Channel Adrenergic Receptor Adenosine Receptor Dopamine Receptor Neurological Disease
    Flavoxate (Rec-7-0040 free base; DW61 free base) is an orally active L-type Ca 2+ channel inhibitor and antispasmodic. Flavoxate inhibits cyclic adenosine monophosphate production by blocking voltage-dependent inward Ba 2+ currents, regulating the brainstem micturition center, and stimulating G protein-coupled receptors. Consequently, Flavoxate induces relaxation of bladder smooth muscle and inhibits isovolumetric rhythmic contractions. Flavoxate effectively increases bladder capacity and alleviates symptoms of urgent urination frequency and pollakiuria caused by overactive bladder. Flavoxate can be used in research on overactive bladder and related voiding dysfunctions .
    Flavoxate
  • HY-B0549AR
    Flavoxate hydrochloride (Standard)

    Rec-7-0040 (Standard); DW61 (Standard)

    		 Reference Standards mAChR Calcium Channel Adrenergic Receptor Adenosine Receptor Dopamine Receptor Neurological Disease
    Flavoxate (hydrochloride) (Standard) is the analytical standard of Flavoxate (hydrochloride). This product is intended for research and analytical applications. Flavoxate hydrochloride (Rec-7-0040; DW61) is an orally active L-type Ca 2+ channel inhibitor and antispasmodic. Flavoxate hydrochloride inhibits cyclic adenosine monophosphate production by blocking voltage-dependent inward Ba 2+ currents, regulating the brainstem micturition center, and stimulating G protein-coupled receptors. Consequently, Flavoxate hydrochloride induces relaxation of bladder smooth muscle and inhibits isovolumetric rhythmic contractions. Flavoxate hydrochloride effectively increases bladder capacity and alleviates symptoms of urgent urination frequency and pollakiuria caused by overactive bladder. Flavoxate hydrochloride can be used in research on overactive bladder and related voiding dysfunctions .
    Flavoxate hydrochloride (Standard)
  • HY-178058
    VU6080824

    		Potassium Channel Others
    VU6080824 (Compound 5s), a derivative of ML-133 (HY-100230), is an inward-rectifier potassium channel (Kir2.1) inhibitor with an IC50 of 0.35  μM. VU6080824 has superior thallium flux and manual patch clamp (MPC) functional potency .
    VU6080824
  • HY-17401S
    Ranolazine-d8 dihydrochloride

    CVT 303-d8 dihydrochloride; RS 43285-d8

    		 Calcium Channel Sodium Channel Autophagy Cardiovascular Disease Cancer
    Ranolazine-d8 (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .
    Ranolazine-d8 dihydrochloride
  • HY-B0280S2
    Ranolazine-d3

    		Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d3 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine-d3
  • HY-B0280S1
    Ranolazine-d8

    		Isotope-Labeled Compounds Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d8 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine-d8
  • HY-B0280S
    Ranolazine-d5

    CVT 303-d5; RS 43285-003-d5

    		 Isotope-Labeled Compounds Sodium Channel Calcium Channel Cardiovascular Disease Cancer
    Ranolazine-d5 is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor . Antianginal agent.
    Ranolazine-d5
  • HY-17401R
    Ranolazine dihydrochloride (Standard)

    CVT 303 dihydrochloride (Standard); RS 43285 (Standard)

    		 Calcium Channel Sodium Channel Autophagy Reference Standards Cardiovascular Disease Cancer
    Ranolazine (dihydrochloride) (Standard) is the analytical standard of Ranolazine (dihydrochloride). This product is intended for research and analytical applications. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP) . Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor .
    Ranolazine dihydrochloride (Standard)
  • HY-177763
    TRPM8 receptor agonist-1

    		TRP Channel Neurological Disease
    TRPM8 receptor agonist-1 (Example 81) is a TRPM8 receptor agonist. TRPM8 receptor agonist-1 can trigger the inward flow of calcium, sodium and other ions within the cell, causing the cell membrane to depolarize and triggering an action potential. TRPM8 receptor agonist-1 can activate signals related to the swallowing reflex and can be used for the research of oropharyngeal dysphagia .
    TRPM8 receptor agonist-1
  • HY-172140
    Ebio3

    		Potassium Channel Neurological Disease
    Ebio3 is a selective potassium channel (KCNQ2) inhibitor with an IC50 of 1.2 nM. Ebio3 binds to the KCNQ2 channel through its hydrophobic tail, causing the S6 helix to move inward, which leads to the closure of the inner gate. The inhibitory effect of Ebio3 is also effective in pathogenic mutants of KCNQ2 (such as R75C and I238L), where it can inhibit outward currents by more than 80%. Ebio3 is expected to be used in the research of neurological diseases such as epilepsy .
    Ebio3
  • HY-108400
    SCH-23390 maleate

    R-(+)-SCH-23390 maleate

    		 Dopamine Receptor 5-HT Receptor Potassium Channel Neurological Disease
    SCH-23390 maleate (R-(+)-SCH-23390 maleate) is a potent and selective dopamine D1-like receptor antagonist with Kis of 0.2 nM and 0.3 nM for the D1 and D5 receptor, respectively. SCH-23390 maleate is a potent and high efficacy human 5-HT2C receptor agonist with a Ki of 9.3 nM. SCH-23390 maleate also binds with high affinity to the 5-HT2 and 5-HT1C receptors. SCH-23390 maleate inhibits G protein-coupled inwardly rectifying potassium (GIRK) channels with an IC50 of 268 nM .
    SCH-23390 maleate
  • HY-P5887
    Tertiapin-RQ

    		Potassium Channel Neurological Disease
    Tertiapin-RQ is an inward rectifier K + channel blocker peptide with antidepressive effect .
    Tertiapin-RQ

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: